

## HR 8920

### The PASTEUR Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Dec 9, 2020

**Current Status:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means

**Latest Action:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, Homeland Security, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Dec 9, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/8920>

### Sponsor

**Name:** Rep. Doyle, Michael F. [D-PA-18]

**Party:** Democratic • **State:** PA • **Chamber:** House

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Ferguson, A. Drew, IV [R-GA-3]	R · GA		Dec 9, 2020
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Dec 28, 2020
Rep. Stewart, Chris [R-UT-2]	R · UT		Dec 28, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Dec 9, 2020
Energy and Commerce Committee	House	Referred To	Dec 9, 2020
Homeland Security Committee	House	Referred To	Dec 9, 2020
Judiciary Committee	House	Referred To	Dec 9, 2020
Natural Resources Committee	House	Referred To	Dec 9, 2020
Veterans' Affairs Committee	House	Referred To	Dec 9, 2020
Ways and Means Committee	House	Referred To	Dec 9, 2020

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
116 S 4760	Identical bill	Sep 30, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## **The Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 or The PASTEUR Act**

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides \$11 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

### **Actions Timeline**

---

- **Dec 9, 2020:** Introduced in House
- **Dec 9, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, Homeland Security, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.